glp 1 agonists vs sglt2 inhibitors GLP1 Receptor SGLT2-I in Preventing CKD in T2DM: An Interview – AJKD Blog TrimRX | GLP-1 vs. Other

[DOI] [PubMed] [Google Scholar] 58.Cooper ME

Krishnan, A., Hadi, Y., Hutson, W

Individuals with call rates below 95% or whose sex in phenotype data did not match X chromosome heterozygosity were excluded

Wilce J, Wilce JA

the insulin glargine group (3.3 ml/min/1.73 m2)

1-8 Recent European Society of Cardiology guidelines for the management of cardiovascular disease (CVD) in patients with diabetes state that GLP-1 RAs (lixisenatide, liraglutide, semaglutide, exenatide extended release [ER], dulaglutide, efpeglenatide) should be considered for glucose-lowering treatment in patients with T2D at risk of or with heart failure (HF